The ADC, and Callio’s wider oncology platform, have been licensed from Singapore’s Hummingbird Bioscience, which shares both a CEO with Callio and a number of the same financial backers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback